VBIV vs. RLYB, ALRN, ELDN, BTAI, CKPT, VHAQ, AFMD, LTRN, MNOV, and LPTX Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Rallybio (RLYB), Aileron Therapeutics (ALRN), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), Viveon Health Acquisition (VHAQ), Affimed (AFMD), Lantern Pharma (LTRN), MediciNova (MNOV), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB ) and VBI Vaccines (NASDAQ:VBIV ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Rallybio has higher earnings, but lower revenue than VBI Vaccines.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 10.4% of VBI Vaccines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
VBI Vaccines received 467 more outperform votes than Rallybio when rated by MarketBeat users. Likewise, 74.40% of users gave VBI Vaccines an outperform vote while only 73.33% of users gave Rallybio an outperform vote.
Rallybio has a net margin of 0.00% compared to Rallybio's net margin of -881.79%. VBI Vaccines' return on equity of -66.59% beat Rallybio's return on equity.
Rallybio currently has a consensus target price of $12.20, indicating a potential upside of 630.54%. Given VBI Vaccines' higher possible upside, equities analysts clearly believe Rallybio is more favorable than VBI Vaccines.
Rallybio has a beta of -1.63, suggesting that its share price is 263% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
In the previous week, VBI Vaccines had 2 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for VBI Vaccines and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat VBI Vaccines' score of 0.93 indicating that VBI Vaccines is being referred to more favorably in the news media.
Summary VBI Vaccines beats Rallybio on 8 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
VBI Vaccines Competitors List
Related Companies and Tools
